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the lung and ameliorates fibrosis
Claudia S Bitencourt1, Priscilla AT Pereira1, Simone G Ramos2, Suely V Sampaio1, Eliane C Arantes3,
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Abstract
Hyaluronidases (HYALs) comprise a group of enzymes that degrade hyaluronic acid (HA). In this report, we reveal
that a single intranasal inoculation of HYAL induces an increase in mononuclear cells within the bronchoalveolar
space demonstrating a mesenchymal-like phenotype, expressing stem cell antigen-1 (SCA-1), CD44 and CD73 but
not CD34, CD45, CD3, CD4, CD8 or CD19. This influx of mesenchymal stem cell (MSC)-like cells was dependent on
leukotriene production within the lung parenchyma. These findings prompted experiments demonstrating that
HYAL treatment potently blocked bleomycin-induced lung injury and fibrosis while decreasing transforming
growth factor (TGF)-b production and collagen deposition. These data suggest that HYAL is a novel and promising
tool to use autologous MSC-like cells in the treatment of pulmonary fibrosis.
Background
The hyaluronidases (HYALs) are a group of enzymes
that regulate hyaluronic acid (HA) metabolism and con-
sequently remodel the extracellular matrix (ECM) [1].
These enzymes are produced by: mammals as a compo-
nent of seminal fluid, plasma and urine [1]; bacteria as a
virulence factor [2,3]; and venomous animals as a non-
toxic component of venoms [1]. HYALs have been used
therapeutically due to their capacity to reduce biological
fluid viscosity, increase vascular permeability and render
tissues more accessible to certain drugs [4].
There is much interest in the HYAL-HA axis in the
treatment of inflammatory disorders [1]. While many
studies demonstrated the involvement of HA in inflam-
matory responses, the involvement of HYALs has been
less well studied [5,6]. Although prior investigations
have measured tissue HA levels or HYAL messenger
RNA (mRNA) levels, few have directly assessed the
effect of HYALs on cell or organ function per se.
Mesenchymal stem cells (MSCs) are pluripotent cells
that can differentiate into a variety of cells, including
osteoblasts, myocytes, adipocytes and chondrocytes.
Recently, it has been demonstrated that MSC can
differentiate along a non-stromal lineage to become
lung epithelial cells [7]. The bone marrow is the princi-
pal source for MSCs [8,9] but these cells have also been
isolated from the umbilical cord [10], fetal membranes
[11] and other tissues. The use of MSCs to regenerate
tissues has been reported as a promising therapy for the
treatment of a variety of diseases [12,13]. However, cel-
lular therapy using MSCs has obstacles, including: the
difficulty of obtaining adequate numbers of these cells
to transplant; adverse effects of the cells or concomitant
immunosuppressive therapies; and the possibility of
infection by opportunistic microorganisms [13-15].
Increasingly, MSC-based therapies have been consid-
ered a promising new means of treating chronic lung
diseases such as pulmonary fibrosis, a progressive,
highly-lethal disorder for which very few effective thera-
pies exist [7,13]. For example, MSCs were shown to
ameliorate bleomycin-induced lung fibrosis in mice, an
effect that was associated with diminished lung damage
and ECM collagen deposition within the lung [16]. In
addition, MSCs obtained from the umbilical cord were
recently reported to diminish bleomycin-induced fibrosis
[10].
In the light of this, we sought to examine the actions
of HYAL therapy on the lung microenvironment and on
pulmonary inflammation. We investigated the effects of
intranasal inoculation (i.n.) of HYAL isolated from
either bovine testes or Tityus serrulatus, a yellow
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scorpion (HYAL-TS). These studies, for the first time,
demonstrate that a single dose of HYAL increased a het-
erogeneous population of mononuclear cells with an
MSC-like phenotype in bronchoalveolar fluid (BALF). In
addition, HYAL therapy reduced bleomycin-induced
fibrosis. These novel results suggest that HYAL therapy
should be further examined as a strategy to treat pul-
monary fibrosis.
Results
HYAL induces late and preferential increases in
mononuclear cell numbers in the bronchoalveolar space
In order to determine the effects of HYAL on the lung
microenvironment, mice were inoculated intranasally
with a single dose containing 4, 8 or 16 U of bovine tes-
ticular HYAL and cells present in BALF were recovered
at different time points. Unexpectedly, we found that
i.n. HYAL induced a late, and almost exclusive, mono-
nuclear cell increase in BALF between 48 and 96 h after
inoculation (Figure 1A and 1B). The maximal effect was
observed at 4 U, with no further increase at 8 or 16 U.
We then administered 16 U of HYAL and observed ani-
mals 96 h post inoculation. Interestingly, 96 h after the
i.n. inoculation of HYAL, oedema formation was not
observed, indicating that this enzyme did not induce an
increase in lung vascular permeability at this time, in
contrast to i.n. lipopolysaccharide (LPS) administration
(Figure 1C). In order to determine whether the cellular
increases in the lung were due to a specific effect of
bovine testicular HYAL, we performed similar experi-
ments with HYAL-TS. As we observed the same profile
obtained using either HYAL or HYAL-TS, we used only
testicular HYAL for future experiments (Figure 1D). In
order to assess whether the increases in cell numbers in
BALF were dependent on enzymatic activity per se,
HYAL was heated and denatured at 60° or 95°C for
60 min, respectively, before inoculation. We observed a
decrease of ~70% in mononuclear cells present in BALF,
compared to the active enzyme (Figure 1E). However,
heated and inactive HYAL still induced a significant
increase in mononuclear cells in BALF compared to
phosphate buffered saline (PBS). HYAL did not induce
alterations in the lung architecture (Figure 1F).
HYAL induces cell recruitment through a mechanism
dependent on leukotrienes, prostaglandins and cytokines
Figure 2 illustrates that interleukin (IL)-1, IL-2, IL-4,
IL-5, IL-10 and TNF-a are significantly increased 96 h
after treatment with 16 U HYAL, suggesting that these
cytokines might be involved in cell recruitment to the
BALF (Figure 2A - H). As lung cells are a rich source of
immunoregulatory lipid mediators, we also quantified
the leukocyte chemoattracting eicosanoid leukotriene B4
(LTB4) in lung parenchyma. LTB4 was significantly
increased compared to PBS (Figure 3A). Figure 3C
shows mononuclear cell numbers recovered from BALF
of mice treated with the leukotriene synthesis inhibitor
MK886 or the anti-inflammatory compound dexametha-
sone. Treatment of mice with dexamethasone decreased
the number of cells recovered from BALF by 76%, com-
pared to those receiving HYAL alone. When compared
to vehicle-treated animals, mononuclear cell numbers
were significantly diminished by MK886 pre-treatment
of HYAL-exposed mice (46%) or celecoxib pre-treat-
ment of HYAL-exposed mice (65%), indicating the parti-
cipation of leukotrienes and prostaglandins (PGs) in
HYAL-induced cell migration (Figure 3C). To further
implicate the involvement of PGs, we measured PGE2
concentrations, which tended to increase in lung homo-
genates after HYAL, but this result was not significant
(Figure 3B). In order to confirm the involvement of leu-
kotrienes in the mononuclear recruitment induced by
HYAL, 5-LO -/- (129-Alox5tm1Fun) and strain-matched
wild type (WT) were injected i.n. with HYAL. The
mononuclear cells obtained from 5-LO -/- BALF after
96 h were significantly diminished in comparison to
WT (Figure 3D). Additionally, other cell types were not
altered by HYAL in 5-LO -/- and WT. These results sug-
gest that HYAL-induced mononuclear cell recruitment
is at least partially dependent on leukotriene, prostaglan-
din and cytokine production.
Immunophenotypic characterization of mononuclear cells
present in BALF
The populations of BALF cells obtained after HYAL
inoculation were studied by flow cytometry and gated
into four distinct sub-populations according to their for-
ward/side scatter patterns. These sub-populations were
referred to as gates 1, 2, 3 and 4. In two of these cell
groups, we observed striking differences in cell numbers
between vehicle (PBS) and HYAL-induced mononuclear
cells (Figures 4, 5, 6, 7, 8). First, we performed analyses
using anti-CD3, CD4, CD8, CD19, MAC-3 and CD11c
immunoglobulins, in order to identify whether these
cells were lymphocytes and/or macrophages. Surpris-
ingly, the expression of these markers was not altered in
bronchoalveolar cells after HYAL exposure. Some sam-
ples showed a decrease in fluorescence intensity, indicat-
ing that the cells that increased in the BALF were not
CD4+ T lymphocytes (CD3+/CD4+), CD8+ T lympho-
cytes, B lymphocytes (CD19+) or macrophages (MAC3+/
CD11c-) (see Additional File 1; Figure S1A - F). In addi-
tion, the decrease of these mature lineage markers sug-
gested that the increased population of cells in the
bronchoalveolar space might be immature or relatively
undifferentiated.
In order to establish the nature of the cellular changes
induced by HYAL exposure, flow cytometric analyses were
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Figure 1 Hyaluronidase (HYAL) induces an increase in leukocytes in bronchoalveolar fluid (BALF) of C57Bl/6 mice. (A) Total cells
obtained from bronchoalveolar space after 4, 24, 48 and 96 h of inoculation with 4, 8 or 16 U of bovine testicular HYAL. Values represent means
± standard error of mean (SEM); n = 4; * P < 0.05 compared to phosphate buffered saline (PBS); ANOVA test was used. (B) HYAL induces almost
exclusively mononuclear cell increases in the bronchoalveolar space after 96 h of inoculation with 16 U of bovine testicular HYAL in C57Bl/6
mice. N.d = not detected. Values represent means ± SEM; n = 4; * P < 0.05, ** P < 0.01 compared to PBS by ANOVA. (C) 16 U HYAL did not
induce oedema after 96 h. The total protein content was measured in BALF. Llopopolysaccharide was inoculated intranasally (i.n.) as a positive
control of oedema (500 μg/μL in 20 μL). Values represent means ± SEM; n = 4; P = 0.003 t test compared to the PBS. (D) Tityus serrulatus
hyaluronidase (HYAL-TS) also induced mononuclear increase in the bronchoalveolar space after i.n. inoculation of 16 U in C57Bl/6 mice. N.d =
not detected. Values represent means ± SEM; n = 5; * P = 0.003 using test t, compared to the PBS. (E) HYAL inactivation by heating reduces
mononuclear cell numbers in bronchoalveolar space. 16 U of bovine testicular HYAL were heated or not at 60°C or 95°C i.n. inoculated and BALF
cells collected 96 h later. Values represent means ± SEM; n = 5; * P < 0.001 compared to PBS; # P < 0.001 compared to active HYAL by ANOVA.
(F) Photomicrographs of representative lung sections obtained from mice inoculated with PBS or HYAL. Tissues were stained with H&E to
investigate inflammatory cells accumulation. Original magnification: 100x.
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performed using hematopoietic and non-hematopoietic
markers on the four sub-populations described above. In
gate 1 (gate 1 in Figures 4 and 5), following HYAL treat-
ment, we observed a decreased in CD34 (42%) and CD45
(23%) expression, increased stem cell antigen-1 (SCA-1;
152%) and CD44 (132%) expression, followed by a mar-
ginal increase in CD73 (39%) compared to PBS-treated
mice (Figure 6). The overlaid histograms showed signifi-
cant changes in the expression of surface marker profiles
comparing PBS and HYAL treatment, where CD44 and
SCA-1 peaks were shifted to the right (Figure 4) as were
the number of events (Figure 5).
The same expression profile was observed in gate 2
(Figures 7 and 8), but CD44 expression was decreased
Figure 2 Hyaluronidase (HYAL) modulates cytokines in the lung parenchyma. Supernatants were prepared from the lung parenchyma
obtained from C57Bl/6 mice treated after 96 h of inoculation with 16 U of bovine testicular HYAL or phosphate buffered saline (PBS). Interleukin
(IL)-1, IL-2, IL-4, IL-5, IL-10, IL-12, tumour necrosis factor (TNF)-a and interferon (IFN)-g were assayed by ELISA. (A) IL-1, P = 0.001; (B) IL-2, P = 0.01;
(C) IL-4, P = 0.004; (D) IL-5, P = 0.006; (E) IL-10, P = 0.08; (F) IL-12, P = 0.54; (G) TNF-a, P = 0.02; (H) IFN-g, P = 0.07; (A-H) = values represent
means ± SEM compared to PBS; n = 5, t test was used.
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compared with gate 1. When compared to PBS, mean
and median fluorescence intensities were similar
(Figures 6 and 9), compatible with the related histo-
grams. The other two gates (3 and 4) did not show the
same profile of marker expression and were uninforma-
tive (see Additional File 2; Figure S2A - F).
Cells labelling positive for SCA-1, CD44, CD73 and
negative for CD34 and CD45 have been described as
murine MSCs. These data provide a basis from which
we can postulate that the cells increased in BALF fol-
lowing HYAL treatment are also MSC-like cells.
MSC-like cells are increased in lung ameliorate the
bleomycin-induced fibrosis
In light of the finding that the cells increased in the
BALF of mice exposed to HYAL were phenotypically
consistent with MSCs-like, we tested the potential of
HYAL to mollify bleomycin-induced pulmonary fibrosis.
Mice were exposed to bleomycin on day 0, and on the
7th day post-bleomycin, inflammatory cells were recov-
ered from the bronchoalveolar space and enumerated in
order to confirm the presence of inflammatory cells. As
expected, bleomycin induced an inflammatory reaction
Figure 3 Hyaluronidase (HYAL) induces mononuclear cell increase in bronchoalveolar space by mechanism partially dependent on
lipid mediators. (A) Leukotriene (LT)B4 presents in the supernatant of lung homogenates were analysed by specific electroimmunoassay. C57Bl/
6 was inoculated intranasally (i.n.) with 16 U of bovine testicular HYAL or phosphate buffered saline (PBS) and the lungs were removed 96 h
later. Values represent means ± standard error of mean (SEM); n = 10; P = 0.04 compared to the PBS; t test was used. (B) Prostaglandin E2
concentration in the supernatant of lung homogenates was analysed by specific electroimmunoassay. C57Bl/6 was inoculated i.n. with 16 U of
bovine testicular HYAL or PBS and the lung was removed 96 h later. Values represent means ± SEM; n = 10; P = 0.15 compared to the PBS
group, t test was used. (C) Pre-treatment with dexamethasone (1 mg/kg s.c.); MK886 (5 mg/kg/0.5 mL by gavage) or celecoxib (5 mg/kg/0.5 mL
by gavage) significantly reduced the number of cells in bronchoalveolar space of C57Bl/6 mice. All treatments were performed 1 h before stimuli
and every 24 h until the end of experiment. Control received only PBS. Values represent means ± SEM.; n = 5; * P > 0.01 compared to PBS; # P
> 0.001 compared to HYAL + PBS, ANOVA test was used. (C) Mononuclear cells recruitment to the bronchoalveolar space of 5-LO -/- (129-
Alox5tm1Fun) mice is decrease when compared to strain-matched wild-type (WT) mice. Each strain was inoculated with 16 U of HYAL and cells
recovered 96 h after stimulus. Values represent means ± SEM; n = 5; * P < 0.0001 compared to PBS WT; # P = 0.0003 compared to PBS 5-LO -/-; #
P = 0.0003 compared to HYAL WT; test t was used.
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with a high number of neutrophils and mononuclear
cells compared to the PBS-inoculated control mice (see
Additional File 3; Figure S3A and B). In addition, groups
of mice inoculated with bleomycin were treated i.n. on
the 8th day post-bleomycin with 16 U of HYAL or PBS
vehicle and inflammatory responses were evaluated 96 h
(4 days) later (Figure 10). This period of treatment cor-
responded to the same time that we observed an
increase in MSC-like cells in the BALF of HYAL-inocu-
lated mice. Interestingly, HYAL led to a non-significant
reduction in neutrophil recruitment following bleomycin
(Figure 10A), followed by a significant increase in
mononuclear cell numbers (Figure 10B). Also, cytokines
involved in the progression of fibrosis were evaluated.
We did not observe alterations in MCP-1 or KC after
HYAL treatment (see Additional File 3; Figure S3C and
D). On the other hand, a significant reduction in TGF-b
concentrations was observed in lung homogenates after
HYAL treatment (Figure 10C).
Figures 10F and 10G illustrate the morphology of the
lung after the inoculation of bleomycin and either
HYAL or PBS treatment. Histopathological findings in
the lungs of mice 12 days after of bleomycin-induced
fibrosis showed sub-pleural and parenchymal foci of
inflammation and fibrosis, following treatment with PBS
(Figure 10F). In contrast, HYAL treatment reduced
bleomycin-induced fibrosis and collagen deposition, as
observed in tissues stained for collagen deposition (Fig-
ure 10G). Tissue collagen deposition was also measured
by picrosirius and a significant decrease was observed
after HYAL treatment (Figure 10D). The total soluble
collagen assayed by Sircol was also decreased compared
with bleomycin treated mice (Figure 10E). These data
together showed that HYAL significantly reduced pul-
monary fibrosis induced by bleomycin instillation.
Discussion
These studies of the effects of i.n. HYAL administration
revealed two surprising and potentially important new
findings. First, we demonstrated that HYAL produced a
profound increase in mononuclear cells in the airways
and these cells had phenotypic features of MSC-like
cells. Second, we showed that treatment with HYAL
reduced the bleomycin-induced fibrotic response in the
lung parenchyma.
We observed that HYAL induced an unusual profile of
cellular migration. Cellular migration into the lung is
usually a result of an inflammatory process and involves
resident cells, soluble mediators and cells that were
recruited to the inflammatory focus [17]. In a typical
acute inflammatory setting, neutrophil recruitment is
chronologically followed by the arrival of other cells,
Figure 4 Hyaluronidase (HYAL) induced an increase in bronchoalveolar cells with a phenotype of mesenchymal stem cells. Gate 1 is a
representative picture showing forward/side scatters dot-plot of bronchoalveolar fluid cells obtained from phosphate buffered saline (PBS)
treatment (black contour-plot) overlaid upon HYAL exposure (grey dot-plot), as well as the gate population highlighted in red. Histograms
overlays were done using the gated population highlighted in red; open histogram = isotype; grey filled histogram = PBS; red filled histogram =
HYAL. The figure depicts a representative analysis from five independent experiments.
Figure 5 Hyaluronidase (HYAL) induced an increase in bronchoalveolar cells with a phenotype of mesenchymal stem cells. Gate 1 is a
representative picture showing forward/side scatters dot-plot of bronchoalveolar cells obtained from PBS treatment (black) overlaid upon HYAL
exposure (red). The figure depicts a representative analysis from five independent experiments.
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including macrophages and lymphocytes, depending on
the stimulus [18]. However, we did not observe neutro-
phils within 4 h after HYAL inoculation, which suggests
that the enzyme was not a pyogenic inflammatory sti-
mulus per se. HYALs comprise a group of enzymes that
can be found in a variety of sources [1]. The substrates
of HYALs vary according to the source of the enzymes.
For example, bovine testes HYAL degrades hyaluronan
and chondroitin, while HYALs obtained from Naja
venom are specific for hyaluronan alone [1]. Considering
these differences, we initially hypothesized that
HYAL-TS might have distinct actions. However, the
T. serrulatus HYAL showed the same profile of cellular
accumulation produced by bovine testes HYAL. As a
result of the similar results, and the difficulty of purify-
ing the enzyme from venom, subsequent experiments
were done using bovine testes HYAL.
In this work, inactive HYAL was used to determine
whether the mononuclear cell increases were due to
alterations in the hyaluronic acid content of the ECM.
Either inactive or denatured HYAL showed a markedly
reduced capacity to induce mononuclear cell infiltration
compared to the active enzyme, establishing that the
enzymatic activity was involved in cell migration into
the alveolar space. In order to verify the mechanisms
involved in this phenomenon, we used diverse pharma-
cological approaches. First, we used dexamethasone, a
potent anti-inflammatory corticosteroid that inhibits leu-
kocyte transmigration, cytokines and lipid mediator
release [19]. These experiments showed that dexametha-
sone reduced the number of cells in the BALF of mice
inoculated with HYAL. In addition to the diminished
recruitment with inactive HYAL, these data suggest that
the cells increased in BALF are not derived from the
lung parenchyma but are the result of new cellular
migration into the lung per se.
Considering the hypothesis that the mononuclear cells
were truly recruited following HYAL treatment, we
Figure 6 Hyaluronidase (HYAL) induced an increase in bronchoalveolar cells with a phenotype of mesenchymal stem cells. The mean
(A) and median (B) expression of markers is altered by HYAL in gate 1. Phosphate buffered saline values were considered to be 100%. The figure
depicts a representative analysis from five independent experiments.
Figure 7 Hyaluronidase (HYAL) induced an increase in bronchoalveolar cells with a phenotype of mesenchymal stem cells. Gate 2 is a
representative picture showing forward/side scatters dot-plot of bronchoalveolar fluid cells obtained from phosphate buffered saline (PBS)
treatment (black contour-plot) overlaid upon HYAL exposure (grey dot-plot), as well as the gate highlighted in red. Histograms overlays were
done using the gated population highlighted in red; open histogram = isotype; grey filled histogram = PBS; red filled histogram = HYAL. The
figure depicts a representative analysis from five independent experiments.
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investigated the role of leukotrienes, which are potent
leukocyte chemoattractants [20]. Treatment with
MK886, an inhibitor of leukotrienes synthesis [21],
reduced the number of cells after HYAL inoculation.
We also used mice that were unable to produce leuko-
trienes (5-LO-/-) and that also had diminished cellular
migration compared to WT animals. In addition, levels
of LTB4 in lung homogenates of HYAL-exposed mice
increased compared with PBS (control) treatment.
Taken together, these results suggested that leukotrienes
(for example, LTB4) are necessary to promote the cellu-
lar migration following HYAL treatment. In order to
explore the involvement of cyclooxygenase (COX)-
derived PGs, we also pre-treated mice with celecoxib, a
drug that inhibits COX-2 with five- to 50-fold selectivity
over COX-1 [22]. Celecoxib-treated mice had a signifi-
cantly diminished cellular migration, indicating that PGs
could be involved in this process, although we did not
find significant increases of PGE2 in the lung homoge-
nates obtained from mice inoculated with HYAL. Future
studies will be important in the determination of the
extent to which other PGs are involved in the effects of
HYAL observed in the present study.
An increase in lung cytokines was observed after inocu-
lation with HYAL. However, as mentioned previously,
HYAL did not induce neutrophil or eosinophil recruit-
ment. Thus, these paradoxical results suggest that a cell-
specific mechanism is involved in MSC recruitment
induced by HYAL and that the basis of this selectivity
requires further investigation. Here, we demonstrated an
increase in IL-10, tumour necrosis factor (TNF)-a, inter-
feron (IFN)-g, IL-1, IL-2, IL-4, and IL-5 following HYAL.
We did not determine the main source of these cyto-
kines, but it is possible that they were produced by
diverse lung cell populations including epithelial cells,
fibroblasts or endothelial cells [23]. In addition, consider-
ing that MSCs have immunosuppressive properties [9]
and synthesize paracrine mediators such as cytokines,
chemokines and other inflammatory mediators [8,24], it
is possible that MSC-like cells might produce these cyto-
kines directly and might also stimulate the immune cells
to produce these mediators.
Figure 8 Hyaluronidase (HYAL) induced an increase in bronchoalveolar cells with a phenotype of mesenchymal stem cells. Gate 2 is a
representative picture showing forward/side scatters dot-plot of bronchoalveolar fluid cells obtained from phosphate buffered saline treatment
(black) overlaid upon HYAL exposure (red). Figure depicts a representative analysis from five independent experiments.
Figure 9 Hyaluronidase (HYAL) induced an increase in bronchoalveolar cells with a phenotype of mesenchymal stem cells. The mean
(A) and median (B) expression of markers was altered by HYAL in gate 2, presented as the percentage of variation compared to the control. The
controls mice were considered to be 100%. The figure depicts a representative analysis from five independent experiments.
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Figure 10 Effects of hyaluronidase (HYAL) treatment on bleomycin-induced inflammation in the lung. At day 8 after bleomycin
treatment (4 U/kg/0.1 mL NaCl 0.9%) in the lungs of C57Bl/6 mice, animals were treated with intranasal inoculation (i.n.) once with 16 U HYAL
or phosphate buffered saline (PBS) and inflammatory cells recovered 96 h after. (A) Neutrophils numbers in the bleomycin-inoculated lung were
not altered by HYAL (P = 0.406). However, (B) mononuclear cells were significantly increased by HYAL treatment (P = 0.045). Values represent
means ± standard error of mean (SEM).; n = 5, by t test (C) transforming growth factor (TGF)-b is increased by bleomycin but reduced by HYAL
treatment. TGF-b was measured in supernatant of lung tissue homogenate by ELISA. Values represent means ± SEM; n = 5, P = 0.0024 compared
to bleomycin, P < 0.0001 compared to PBS, by t test. (D) The picrosirius morphometric analysis corresponding to the area occupied by the fibres
were determined by digital densitometry recognition and expressed as a percentage of the total area of the field. Values represent means ±
SEM; n = 10; P = 0.010 compared to PBS treated, using t test. (E) Acid-soluble collagen in the supernatant of lung tissue homogenate, assayed
by Sircol. Values represent means ± SEM; n = 10; P = 0.010 compared to PBS, by t test. (F, G) Photomicrographs of representative lung sections
obtained from mice inoculated with bleomycin and treated with PBS or with HYAL. In (F) tissues were stained with haematoxylin and eosin in
order to investigate inflammatory cells accumulation and in (G) with Picrosirius to determine the collagen content. The histological analyses
were single-blinded. Original magnifications = 100x.
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Somewhat unexpectedly, a significant increase in
mononuclear cells was observed in the BALF of HYAL-
inoculated mice. Markers of a mature cell lineage had
diminished expression in these cells. These results indi-
cated that the populations increased in BALF were most
likely to be non-differentiated cells. Our hypothesis was
that these cells could be MSCs. However, selecting
appropriate markers of such cells in mice was challen-
ging. Depending on the source and the strategies used
to obtain MSCs, the cellular markers used to describe
human MSCs can vary. In fact, there is no consensus
about the range of specific markers to be used in order
to define a human MSC. To clarify the panel of charac-
teristics necessary for cells to be deemed MSC, The
International Society for Cellular Therapy recently pub-
lished minimal criteria for human MSC. This work did
not encourage the use of the same criteria for murine
MSC because they considered that murine surface mar-
kers have not been universally characterized as well as
for the human MSC [25]. Meirelles et al. considered
that the panel of markers may be adjusted in MSC
obtained from non- bone-marrow sources [8]. There is
no consensus to define a murine MSC and the markers
can change depending on the cell stage [26]. In our
work, we sought to examine the most common markers
used to characterize both human and murine MSC.
Bone marrow murine MSC have been characterized as
CD11b, CD31, CD34, CD45, CD48, CD90, CD117,
CD135 negative and CD29, CD44, CD81, CD105 posi-
tive, whereas MSC obtained by immunodepletion
express CD9, CD29, CD44, CD81 and CD106 [27].
In our flow cytometry studies, we found that BALF
cells from HYAL mice: had positive and high-level
expression for some markers (SCA-1, CD44); were posi-
tive for others (CD73); and were CD34, CD45 negative,
compared to cells derived from PBS-treated animals. In
addition, HYAL populations did not present significant
differences in the expression of CD3, CD4 and/or CD8,
excluding the possibility of these cells being lympho-
cytes. Although murine MSC do not have highly-specific
markers, generally they are CD34neg, CD45pos, CD73neg,
CD44pos and SCA-1pos [8,27,28]. Human MSCs have
been characterized in the literature with many different
markers, depending on the source from which the cells
were isolated [29,30]. Indeed some differences related to
marker expression might be a consequence of the fact
that MSCs are often purified using repeated culture pas-
sages. The cells in the present studies were obtained
directly from the lung without an additional purification
process. Based upon our immunophenotyping data we
considered that the cells induced by HYAL instillation
were MSC-like cells.
Considering that inhaled HYAL treatment recruited
MSC-like cells to the lung, we hypothesized that this
enzyme could treat pulmonary disorders currently ame-
liorated by MSC therapy. Lung disorders such as fibrosis
have been considered to be potential targets for MSC
therapy, due to the capacity of bone marrow-derived-
MSC to differentiate into diverse lung cells [13]. In one
study, mice with fibrosis induced by bleomycin had
diminished damage and collagen deposition in the lung
due to the migration of MSC [16]. In another recent
study, MSC from the umbilical cord diminished fibrosis
induced by bleomycin [10]. Our results showed that
HYAL reduced the histopathological evidence of fibrosis
in the lung by decreasing the number of neutrophils,
collagen content and the production of TGF-b.
We speculate that MSC-like cells are recruited to the
fibrotic lung and differentiate into lung epithelial cells,
ameliorating the fibrosis. This idea is supported by the
evidence that MSC are able to migrate to injured tissues
[13,31]. Bronchiolar stem cells have been defined by the
expression of CD45neg, CD31neg, CD34neg, SCA-1low and
AFlow [32], which are different from the cells induced by
HYAL treatment. Additionally, HYAL treatment inhib-
ited TGF-b production. TGF-b is directly involved in
the progression of fibrosis and its blockade constitutes
an effective treatment of fibrosis. This was demonstrated
in a bleomycin model using TGF-b soluble receptor
with antifibrotic potential in vivo [33]. It is also possible
that some of the effects on fibrosis are the result of the
direct action of HYAL on HA itself. HA is increased in
lung fibrosis and this has been correlated with tissue
damage and inflammation [3,5,6]. A high amount of HA
in the lungs following pro-fibrotic injury is associated
with inflammation due to increases in macrophage loco-
motion [5]. Another important aspect is related to
CD44, the receptor of HA. CD44 has a critical role in
resolving lung inflammation, as CD44-deficient mice
have persistent inflammation with accumulation of HA
fragments and increased activation of TGF-b1 [34].
Thus, we speculate that the decrease in bleomycin-
induced lung fibrosis after treatment with HYAL might
be due to the actions on HA on the regulation of
inflammation, on decreased TGF-b and on the increased
recruitment of MSC-like cells to the lung. It should be
noted that MSCs have also been reported to differenti-
ate into fibrocytes and contribute to the pathogenesis of
pulmonary fibrosis [35] and that bone-marrow derived
fibroblasts are thought to be involved in the progression
of bleomycin-induced fibrosis [36].
Classical stem cell therapy holds great promise but has
some potential negative aspects such as an increased
risk for bacterial infections, viral infections and allergic
reactions [15,37]. A major obstacle to MSC therapy has
been the difficulty of obtaining enough cells to trans-
plant and a lack of standardized and efficient methods
to obtain these cells [14]. Regarding MSC use in the
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treatment of treat lung diseases, these cells represent a
promising modality due to their characteristic migration
to injured tissue, intrinsic immunosuppressive properties
and plasticity to differentiate into mature lung cells
required for the lung repair [13].
In summary, we have newly demonstrated that a sin-
gle dose of HYAL therapy promotes endogenous MSC-
like accumulation in the lung and that this intervention
might prove beneficial to the therapy for serious dis-
eases such as pulmonary fibrosis.
Conclusions
These studies demonstrated that the i.n. administration
of HYAL produced a profound increase in mononuclear
cells, with phenotypic features of MSC-like cells, in the
airways. HYAL is a novel and promising tool for the
recruitment of autologous MSC-like cells to the lungs in
the treatment of pulmonary fibrosis because i.n. HYAL
treatment potently blocked bleomycin-induced lung
injury and fibrosis while it decreased TGF-b production
and collagen deposition. The involvement of lipid med-
iators in this process might also lead to the identifica-
tion of new pharmacological tools for ameliorating
pulmonary fibrosis.
Materials and methods
Animals
C57BL6/6 mice (18-25 g), obtained from the animal
facilities of the Faculdade de Ciências Farmacêuticas de
Ribeirão Preto, Universidade de São Paulo (FCFRP -
USP). Mice lacking 5-LO enzyme gene (5-LO-/-) were
from The Jackson Laboratory and raised at FCFRP -
USP and age-matched male WT (WT-background,
strain 129) used as controls. All experiments were
approved by the guidelines of the Animal Care Commit-
tee of the Universidade de São Paulo (Protocol No.
07.1.782.53.8).
Reagents
In the majority of the experiments bovine HYAL was
used (purchased from Sigma Chemical Co, MO, USA).
In some experiments, HYAL was isolated from the
venom of T. serrulatus, HYAL-TS. MK886 was a gift
from Merck Frosst Canada Inc (ON, Canada). Dexa-
methasone was purchased from Aché© (Laboratórios
Farmacêuticos S/A, São Paulo, Brazil). Bleomycin sul-
phate was purchased from Bristol Myers-Squibb (Blenox-
ane®; São Paulo, Brazil). ELISA antibodies to measure
cytokines were from Pharmingen (CA, USA). Neutravi-
din-horseradish peroxidase was from Perbio Science
(Cheshire, UK). K-Blue substrate was from Neogen (KY,
USA). Panoptic staining was from Laborclin (Paraná,
Brazil). Sircol Collagen Assay was purchased from Biolo-
cor Life Science Assays (Carrickfergus, CA, UK).
HYAL activity and inactivation
HYAL activity was determined turbidimetrically follow-
ing protocol described by Pukrittayakamee and modified
slightly [38]. For heat inactivation, 100 U of HYAL was
heated for 30 min at 60°C [38]. For heat denaturation,
HYAL was heated at 95°C for 60 min.
HYAL experimental design and bleomycin lung injury
Mice were i.n. inoculated with 4, 8 or 16 U of HYAL
(Sigma Chemical Co). Controls received PBS. At 4, 24,
48, 96, 240 or 360 h after treatment, animals received
carbon dioxide for euthanasia. In some experiments
mice received dexamethasone (1 mg/kg weight s.c.); or
MK886 (5 mg/kg/0.5 mL by gavage) 1 h before HYAL.
Mice that were killed 96 h after stimulus received extra
doses every 24 h [39]. Inactive and denaturated HYAL
were used in some experiments. Bleomycin sulphate was
administered intratracheally 4 U/kg in 0.1 of NaCl 0.9%
[16]. After 7 days of bleomycin, animals were treated i.n.
with HYAL 16 U or PBS.
Collection of bronchoalveolar space cells
The trachea was exposed and catheterized. PBS was
infused in three 1-mL aliquots in the catheterized tra-
chea and the cells collected. Total cell counts were per-
formed in a Neubauer chamber. Differential counts were
obtained using Panoptic staining (similar to Diff-
Quick®).
Immunophenotyping of cells by flow cytometry
CD3, CD4, CD8, CD19, CD11c, MAC-3, CD45, CD34,
CD73, SCA-1(Ly-6AE) expression were determined
through flow cytometry immunostaining protocol using
antibody conjugated with fluorochomes (BD Biosciences,
NJ, USA). Specific rat IgG2a isotype controls were used to
monitor non-specific binding. Stained cells obtained from
a BALF pool were washed with PBS containing 2% fetal
bovine serum (FBS), pelleted by centrifugation at 400x g
and fixed with PBS containing 1% (w/v) paraformaldehyde.
A total of 10,000 events were acquired (FACSCanto TM;
Becton Dickinson, CA, USA), using the FACS Diva for
data acquisition and FlowJo for analysis.
Cytokines, leukotrienes and prostaglandin measurements
LTB4 was quantified in lung homogenate using com-
mercial ELISA kits (Cayman Chemical©, MI, USA). IL-
1, IL-2, IL-4, IL-5, IL-10, IL-12, TNF-a, IFN-g, TGF-b,
MCP-1 and KC were determined by ELISA according to
manufacturer instructions (BD Biosciences). Sensitivities
were >10 pg/mL.
Collagen assay
Lung homogenate supernatants were placed in 1.5 mL
tubes. Sircol-dye was added, the content of the tubes
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homogenized for 30 min and centrifuged for 10 min
(10,000x g). The pellets were dissolved with alkaline
reagent. Absorbance was read at 540 nm. The total
soluble collagen was determined using a standard
curve [40].
Histopathological studies
Lung were collected and immediately fixed in 10% for-
malin. Specimens were processed, embedded in paraffin
and cut into for to six lm sections and stained with hae-
matoxylin and eosin (H&E). For evaluation of collagen
fibres in the pulmonary parenchyma, the slides were
stained with Picro Sirius [41]. The surface density of
collagen fibres in the lung was determined by optical
density by image analysis. The system used consisted of
a video camera (Leica Microsystems Ltd, Heebrugg,
Switzerland), applied to a Leica microscope DMR (Leica,
Microsystems GmbH, Wetzlar, Germany) attached to a
computer. The images were processed by software Leica
QWin software (Leica Microsystems Image Solutions,
Cambridge, UK). The thresholds for collagen fibres were
established for each slide, after adjusting the contrast to
a point at which the fibres were easily identified as red
bands. Bronchovascular bundles were carefully avoided
during the measurements. Ten randomly selected
inflammatory foci presented in the pulmonary parench-
yma were considered for each group at 400x. The total
area examined for group was 0.8 mm2. The means was
calculated and the values expressed as a percentage.
Statistical analysis
Data are expressed as mean ± standard error of mean.
Statistical variations were determined by analysis of var-
iance (ANOVA) and Student’s t-test. Values of P < 0.05
were considered significant.
Additional material
Additional File 1: Figure S1. The expression of CD3, CD4, CD8,
CD19, MAC-3 and CD11c in bronchoalveolar fluid (BALF) cells. (A)
Gate 1 is a representative picture showing forward/side scatters
dot-plot of BALF cells obtained from phosphate buffered saline (PBS)
treatment (black contour-plot) overlaid upon hyaluronidase (HYAL)
exposure (grey dot-plot), as well as the gate population highlighted in
red. Histogram overlays were done using the gated population
highlighted in red, where the open histogram is the isotype; the grey
filled histogram represents PBS treatment; red filled histogram represents
HYAL. Figure depicts a representative analysis from five independent
experiments. The mean (B) and median (C) expression of markers is
altered by HYAL. PBS values were considered 100%. (D) Gate 2 is a
representative picture showing forward/side scatters dot-plot of BALF
cells obtained from PBS treatment (black contour-plot) overlaid upon
HYAL exposure (grey dot-plot), as well as the gate of interest highlighted
in red. Histogram overlays were done using the gated population
highlighted in red, where the open histogram is for the isotype control;
grey filled histogram represents PBS treatment; red filled histogram
represents HYAL. The figure depicts a representative analysis from five
independent experiments. The mean (E) and median (F) expression of
markers is altered by HYAL. PBS values were considered 100%.
Additional File 2: Figure S2. Cells induced by 16 U of bovine
testicular hyaluronidase (HYAL) to the bronchoaveolar fluid (BALF)
of C57Bl/6 mice. (A) Gate 3 is a representative picture showing forward/
side scatters dot-plot of BALF cells obtained from phosphate buffered
saline (PBS} treatment (black contour-plot) overlaid upon HYAL exposure
(grey dot-plot), as well as the gate of interest highlighted in red.
Histograms overlays were done using the gated population highlighted
in red; open histogram = isotype control; grey filled histogram = PBS
treatment; red filled histogram = HYAL treatment. The figure depicts a
representative analysis from five independent experiments. (B) Gate 3 is a
representative picture showing forward/side scatters dot-plot of BALF
cells obtained from PBS treatment (black) overlaid upon the HYAL
exposure (red). The figure depicts a representative analysis from five
independent experiments. The mean (C) and median (D) expression of
markers is altered by HYAL. PBS values were considered 100%. (E) Gate 4
is a representative picture showing forward/side scatters dot-plot of BALF
cells obtained from PBS treatment (black contour-plot) overlaid upon
HYAL exposure (grey dot-plot), as well as the gate of interest highlighted
in red. Histograms overlays were done using the gated population
highlighted in red; open histogram = isotype control; grey filled
histogram = PBS treatment; red filled histogram = HYAL treatment. The
figure depicts a representative analysis from five independent
experiments. (F) Gate 4 is a representative picture showing forward/side
scatters dot-plot of BALF cells obtained from PBS treatment (black)
overlaid upon HYAL exposure (red). The figure depicts a representative
analysis from five independent experiments. The mean (G) and median
(H) expression of markers was altered by HYAL, presented as the
percentage of variation compared to control. The controls mice were
considered 100%.
Additional File 3: Figure S3. Effects of hyaluronidase (HYAL) on
bleomycin-induced inflammation in the lung. (A) Neutrophils
numbers in the bleomycin inoculated mice were significantly increased 7
days after inoculation (P > 0.001). Values represent means ± standard
error of mean (SEM); n = 5, Student t test was used (B) mononuclear
cells in bleomycin inoculated mice were significantly increased 7 days
after inoculation (P > 0.0001). Values represent means ± SEM;
n = 5, test t was used. (C) MCP-1 concentration in supernatant of lung
tissue homogenate was determined by ELISA. Values represent means ±
SEM; n = 5, P = 0.9526 compared with bleomycin; Student t test was
used. (D) KC concentration in supernatant of lung tissue homogenate
was determined by ELISA. Values represent means ± SEM; n = 5,
P = 0.3063 compared with bleomycin; Student t test was used.
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